Drug intelligence / Profile preview

CPP-001

Development stage: Preclinical
Lead developer: CrossPoint Therapeutics
Modality: Recombinant Proteins and Enzymes

Overview

CPP-001 is a discovery-stage immuno-oncology therapeutic candidate being developed by CrossPoint Therapeutics. It is built using the company's proprietary 'Stealth-Body' technology, a smart cell-targeting delivery platform designed for the precise delivery of proteins. CPP-001 is characterized as a dual-targeting agent that utilizes a natural ligand for its mechanism and is engineered to have no Fc effector function, which is intended to minimize off-target immune activation. The specific biological targets for this program are currently undisclosed.

Beyond the preview

Go deeper on CPP-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CPP-001.

Explore the full profile